77 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
22 Recruiting Survey of Inhibitors in Plasma-Product Exposed Toddlers
Condition: Hemophilia A
Interventions: Drug: PLASMA DERIVED Factor VIII;   Drug: Recombinant FVIII
23 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
24 Recruiting Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Condition: Hemophilia A
Intervention:
25 Recruiting Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
Condition: Hemophilia A
Intervention: Procedure: Laboratory Tests
26 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
27 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
28 Recruiting Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
Condition: Severe Hemophilia A With Inhibitor
Intervention: Other: TGA (Thrombin generation Assay)
29 Recruiting Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
30 Recruiting Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
31 Recruiting Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
Condition: Hemophilia A
Intervention: Biological: Moroctocog alfa (AF-CC)
32 Recruiting Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
Condition: Hemophilia A
Intervention: Device: Refacto FusENGO
33 Recruiting Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human-cl rhFVIII
34 Recruiting ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
Conditions: Hemophilia A;   Congenital Factor VIII (FVIII) Deficiency
Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
35 Recruiting Pharmacokinetics of BIIB031 at 2 Vial Strengths
Condition: Severe Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)
36 Recruiting China ADVATE PTP Study
Condition: Hemophilia A
Intervention: Biological: Octocog alfa (recombinant human coagulation factor VIII)
37 Recruiting Human-cl-rhFVIII in Previously Untreated Patients
Condition: Severe Hemophilia A
Intervention: Biological: Human cl rhFVIII
38 Unknown  A Prospective, Randomized, Cross-Over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
Condition: Hemophilia A With Inhibitors
Intervention: Drug: activated prothrombin complex concentrate (FEIBA)
39 Unknown  Non Neutralizing Antibodies: Prevalence and Characterization
Condition: Hemophilia A
Intervention: Biological: blood test
40 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years